8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2021 (January 12, 2021)

LUMINEX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	000-30109	74-2747608
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

	12212 Technology Blvd.,	Austin,	Texas	78727
(Address of principal executive offices)				(Zip Code)

	(512)	219-8020
Registrant’s Telephone Number, Including Area Code

None

(Former name or former address, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock, $0.001 par value	LMNX	The Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
	Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
	☐

Item 2.02. Results of Operations and Financial Condition.

On January 12, 2021, Luminex Corporation (“the Company”) issued a press release announcing preliminary revenue for the fourth quarter and full year 2020.  A copy of the press release is furnished herewith as Exhibit 99.1.

The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01. Regulation FD Disclosure.

On January 13, 2021, the Company is giving a presentation (“Investor Presentation”) to investors discussing, among other topics, an overview of the Company’s business and growth strategy. The presentation will be at the 39th Annual J.P. Morgan Healthcare Conference, to be held virtually, and will begin at 3:30 p.m. Central Time (4:30 p.m. Eastern Time).  A copy of the Investor Presentation, which is available at www.luminexcorp.com, is being furnished as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release issued by Luminex Corporation dated January 13, 2021.
99.2	Investor Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	LUMINEX CORPORATION
Date: January 12, 2021	By:	/s/ Harriss T. Currie
	Name:	Harriss T. Currie
	Title:	Chief Financial Officer, Senior Vice President of Finance
		(Principal Financial Officer)

EX-99.1

Exhibit 99.1

Luminex Corporation Pre-Release of 4th Quarter 2020 Revenue

Fourth Quarter Earnings Call Scheduled for February 8, 2021

AUSTIN, Texas, January 12, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 4th quarter 2020 revenue of approximately $111M, up approximately 23% over the 4th quarter of 2019 and full-year revenue of approximately $417M, up approximately 25% over the full year 2019. Fourth quarter and full year highlights include:

•Total molecular diagnostics (MDx) revenue for full-year 2020 of $228M, up approximately $91M from $137M in 2019.

•Placed approximately 450 sample-to-answer systems in 2020, up approximately 120% vs. 2019 placements, including 40+ VERIGENE® II RUO systems shipped ex-US during the 4th quarter.

•Licensed Technologies Group revenue for full-year 2020 of approximately $147M, down approximately 2% from full-year 2019 revenue of $149M, with approximately $40M of revenue generated in the 4th quarter.

•Flow Cytometry revenue for full-year 2020 of approximately $36M, down approximately 20% from full-year 2019 of $45M, with approximately $12M of revenue generated in the fourth quarter.

•Commenced production on expanded ARIES® manufacturing line, with current capacity of more than 4M tests per year.

In addition, as of the date of this release, Luminex is raising its previously provided 2021 revenue guidance to reflect that the Company currently expects 2021 revenue to be approximately $480M, which would represent a 15% increase from 2020 full-year revenue.

“I am extremely pleased with our results. We ended 2020 with both record quarterly and annual revenue and believe that we are well prepared for continued growth in 2021,” said Nachum “Homi” Shamir, Chairman, CEO and President. “Our diversified model performed well across our business during the quarter. Our strength in molecular diagnostics continued, in advance of the continued expansion of our ARIES® manufacturing capacity. Our partners experienced a recovery in their businesses and performed well. And our flow cytometry business saw a similar recovery in the back half of the year as facilities around the world began to open up. With the breadth of opportunities in front us, we are excited to have ended the year on such a strong note and are heading into 2021 anticipating another very strong year.”

The results reported herein are preliminary, based on management's initial analysis of operations for the quarter and year ended December 31, 2020 and subject to further internal review and audit by the Company's external auditors. Luminex’s full financial results for the fourth quarter and full-year 2020 will be discussed on its fourth quarter earnings call, currently scheduled for February 8, 2021.

About Luminex Corporation

At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We accelerate reliable answers while simplifying complexity and deliver certainty with a seamless experience. To learn more about Luminex, please visit us at luminexcorp.com.

Use of Forward-Looking Statements

Statements made in this release that express Luminex’s or management's intentions, plans, beliefs, expectations, or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding Luminex’s expected financial results for the fourth quarter of 2020 and full-year 2020 and its projected 2021 performance, including revenue guidance. The words "expect," "anticipate," "will," "could," "should"

and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that Luminex’s actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex’s actual results or performance to differ materially include risks and uncertainties relating to, among others, negative effects from the worldwide COVID-19 pandemic (including but not limited to the general economic downturn related to such pandemic, travel restrictions related thereto, business closures that may affect Luminex’s supply chain or its ability to install instruments, and delays in U.S. Food and Drug Administration (the “FDA”) clearances related to adjustments in the agency’s approval priorities in response to the pandemic); the warning letter (the “Warning Letter”) Luminex received from the FDA on June 26, 2020 relating to the operations of Luminex’s Austin, TX and Northbrook, IL facilities and Luminex’s VERIGENE Processor SP System, as previously disclosed in Luminex’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 29, 2020, including the outcome of Luminex’s efforts to remediate the FDA’s observations, the possible resolution of the issues identified in the Warning Letter and any further regulatory and enforcement actions that may initiated by the FDA with respect thereto; concentration of Luminex’s revenue in a limited number of direct customers and strategic partners, some of which may be experiencing decreased demand for their products utilizing or incorporating Luminex’s technology, budget or finance constraints in the current economic environment, or periodic variability in their purchasing patternsor practices as a result of internal resource planning challenges; market demand and acceptance of Luminex’s products and technology, including ARIES®, MultiCode®, xMAP®, xMAP® INTELLIFLEX, VERIGENE®, VERIGENE® II, Guava®, Muse®, Amnis® and NxTAG® products; Luminex’s ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels; Luminex’s ability to obtain and enforce intellectual property protections on Luminex’s products and technologies; the impact on Luminex’s growth and future results of operations with respect to the loss of the LabCorp women’s health business; Luminex’s ability to successfully launch new products and complete new manufacturing lines in a timely manner; dependence on strategic partners for development, commercialization and distribution of products; risks and uncertainties associated with implementing Luminex’s acquisition strategy, including any challenges in identifying acquisition targets and obtaining financing on acceptable terms; Luminex’s ability to integrate acquired companies or selected assets into Luminex’s consolidated business operations and its ability to fully realize the benefits of Luminex’s acquisitions; the timing of and process for regulatory approvals; competition and competitive technologies utilized by Luminex’s competitors; fluctuations in quarterly results due to a lengthy and unpredictable sales cycle; fluctuations in bulk purchases of consumables; fluctuations in product mix and the seasonal nature of some of Luminex’s assay products; Luminex’s ability to comply with applicable laws, regulations, policies and procedures; the impact of the ongoing uncertainty in global finance markets and changes in governmental and governmental agency funding, including effects on the capital spending policies of Luminex’s partners and end users and their ability to finance purchases of Luminex’s products; changes in principal members of Luminex’s management staff; potential shortages, or increases in costs, of components or other disruptions to Luminex’s manufacturing operations; Luminex’s increasing dependency on information technology to improve the effectiveness of Luminex’s operations and to monitor financial accuracy and efficiency, including risks associated with potential attacks on or breaches of Luminex’s information technology systems and any resultant harm to Luminex’s ability to protect its intellectual property and manufacture, sell and support its products; the implementation, including any modification, of Luminex’s strategic operating plans; the uncertainty regarding the outcome or expense of any litigation brought against or initiated by Luminex; risks relating to Luminex’s foreign operations, including fluctuations in exchange rates, tariffs, customs and other barriers to importing/exporting materials and products in a cost effective and timely manner; difficulties in accounts receivable collections; Luminex’s ability to monitor and comply with foreign and international laws and treaties; Luminex’s ability to comply with changes in international taxation policies; reliance on third party distributors for distribution of specific Luminex-developed and manufactured assay products, as well as the risks discussed under the heading "Risk Factors" in Luminex’s Reports on Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements, including the preliminary fourth quarter 2020 and full-year 2020 results and 2021 projected performance, including revenue guidance, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contacts

Investor Contact:

Harriss Currie

Senior Vice President of Finance and Chief Financial Officer

hcurrie@luminexcorp.com

512-219-8020

Investor Relations Contact:

Carla Stanaford

cstanaford@luminexcorp.com

937-469-2120

Media Contact:

Michele Parisi

Bioscribe

mparisi@bioscribe.com

925-864-5028

EX-99.2

JANUARY 2021 Homi Shamir Chairman, President and CEO INVESTOR PRESENTATION

complexity simplif ied. 2 SAFE HARBOR STATEMENT This presentation is being made exclusively to investors that are both institutional accredited investors (within the meaning of Rule 501 promulgated under the Securities Act of 1933, as amended (the “Securities Act”)) (“IAIs”) and qualified institutional buyers (“QIBs”) as defined in Rule 144A (“Rule 144A”) under the Securities Act. The securities described herein have not been and will not be registered under the Securities Act and may not be offered or sold in the United States except to investors that are both IAIs and QIBs in reliance on Section 4(a)(2) of the Securities Act or pursuant to another exemption from, or transaction not subject to, the registration requirements of the Securities Act. This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in any jurisdiction where such offer or sale is not permitted. Any purchaser of such securities will be deemed to have made certain representations and acknowledgments, including, without limitation, that the purchaser is both an IAI and a QIB. Certain statements made during the course of this presentation may not be purely historical and consequently may be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements made regarding: our Licensed Technologies Group model and the ability of our licensees and installed base to drive future growth; the ability of our technology to enhance productivity and efficiency; our financial position and long-term revenue growth; our molecular diagnostic business model, the markets we are targeting, market segmentation, expected growth of such markets, and the ability of our products to address those markets; sales of our products, their technical capabilities, and the anticipated market size and acceptance, demand and regulatory environment and approvals therefor; our direct sales efforts; our system placements; our system and assay product pipeline and anticipated timelines for regulatory approvals and market releases, including for ARIES® and VERIGENE® instrumentation and assays, and our flow cytometry product lines; market opportunity for ARIES®, VERIGENE®, and our flow cytometry products; functionality and benefits of ARIES®, VERIGENE®, and the flow cytometry products and competitive position; reimbursement trends; our ability to drive growth through investment in R&D and next generation systems and focus on operating leverage and managing operating costs; our long-term financial targets; our key steps and strategies for growth; our strategic outlook and growth plan for our business for 2021 and beyond; operational trends, including those related to sales of systems, assays, consumables, and royalty revenues; competitive threats and products offered by other companies; our business outlook, financial targets and projections about revenues, cash flows, system shipments, expenses and market conditions, and their anticipated impact on Luminex for 2021 and beyond; and, any statements of the plans, strategies and objectives of management for future operations. These forward-looking statements speak only as of the date hereof and are based on our current beliefs and expectations and are subject to known or unknown risks and uncertainties, some of which are beyond our control, that could cause actual results or plans to differ materially and adversely from those anticipated in the forward-looking statements. Factors that could cause or contribute to such differences are detailed in our annual, quarterly, or other filings with the Securities and Exchange Commission. We undertake no obligation to update these forward-looking statements. Also, certain non-GAAP financial measures, as defined by SEC Regulation G, may be covered in this presentation. To the extent that any non-GAAP financial measures are covered, a presentation of and reconciliation to the most directly comparable GAAP financial measures will be included in this presentation and may be available on our website at luminexcorp.com in accordance with Regulation G.

complexity simplif ied. 3 LUMINEX CORPORATION: FULLY EMBEDDED IN GLOBAL BIOMEDICAL SCIENCE AND HEALTHCARE ENTERPRISES Actionable solut ions across the biomedical spectrum Luminex is a biotech company providing molecular, proteomic, and cellular analysis tools and tests to life science and diagnostics markets exceeding $12B per year. We seek to enable labs around the world to quickly advance science and deliver beneficial, cost-effect ive healthcare solut ions

complexity simplif ied. 4 LUMINEX CORPORATION: WHO WE ARE • Differentiated platforms and assays to address the needs of our clinical, biopharmaceutical, and research customers • Enabling molecular, proteomic, and cellular analysis DIVERSIFIED SOLUTIONS • Serving a growing $12B+ global life science marketplace • Flexibility in reaching customers through direct sales, strategic partnerships, and other channels ATTRACTIVE MARKETS • Healthy profitability, increasing quarterly dividend, consistent cash flow and strong balance sheet • ~25,000 instruments worldwide driving 75% annuity revenue FINANCIAL STRENGTH & GLOBAL REACH

complexity simplif ied. 5 LEADING CUSTOMERS & PARTNERS

complexity simplif ied. 6 LUMINEX ADDRESSES A $12B+ GLOBAL MARKET ACADEMIC GOVERNMENT BIOPHARMA / BIOTECH APPLIED TESTING HOSPITAL / REFERENCE LABS ARIES®  VERIGENE®  VERIGENE® II  MAGPIX®      LX200/ FM3D      xMAP® INTELLIFLEX     Guava® easyCyte™    ImageStream®   

complexity simplif ied. 7 COMPANY IS ON TRACK TO NEARLY TRIPLE ANNUAL REVENUE SINCE 2011 $184M $203M $213M $227M $238M $270M $306M $315M $335M $417M 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021G $480M

complexity simplif ied. 8 RECURRING REVENUE DRIVES LMNX GROWTH $0M $50M $100M $150M $200M $250M $300M $350M $400M $450M 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 of revenue is recurring 75% Assays Consumables Systems Other Royalties

complexity simplif ied. 9 ANNUAL EBITDA SINCE 2011 REVENUE GROWTH AND MARGIN FOCUS DRIVE EBITDA PROGRESSION $36M $37M $21M $42M $51M $41M $60M $52M $19M 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 LABCORP DEPARTURE RESTRUCTURING COSTS 2021 YTD thru Q3 $53.5M

PANDEMIC SOLUTIONS

complexity simplif ied. 11 DEVELOPING SOLUTIONS DURING THE COVID-19 PANDEMIC PCR-BASED TESTS • Two Luminex PCR-based COVID-19 tests have already received EUA clearance • Run on ARIES® and NxTAG® Systems • Anticipate Q1 2021 EUA for a number of multiplex panels that have SARS-CoV-2 targets, including on ARIES®, VERIGENE® II and NxTAG® Systems ANTIGEN-BASED TESTS • xMAP® Multi-Antigen IgG assay has received EUA clearance • Developing additional antibody tests to help identify individuals who may have some level of immunity to the virus

complexity simplif ied. 12 EXPANDED MANUFACTURING TO MEET INCREASED DEMAND Chicago/ VERIGENE® • ~25% increase in footprint ($8M facility purchase). Q1 2021 • 600K test capacity (VERIGENE II fully automated lines) • 1.2M test capacity (VERIGENE I) • $3.4M total investment (already paid) Madison/ Reagents • 10%+ increase in building footprint (investment of $2.5M) • Supports both ARIES® and VERIGENE II Austin/ARIES® • 600K test capacity. Beginning of 2020 • 1.6M test capacity. Summer 2020 • 3.2M test capacity (investment of ~$5M). Ready now! • 4.5M test capacity (investment of $1M). Mid-2021 • 6M+ test capacity (investment of ~$5M). Beginning of 2022 • 50K sq ft facility expansion. Mid-2021 Toronto/ NxTAG® • 1M test capacity. Beginning of 2020 • 9M test capacity (investment of $500K). Summer 2020

SUMMARY

complexity simplif ied. 14 These efforts have allowed us to be well posit ioned for cont inued growth in profitability, while avoiding the “COVID-19 cliff” that many companies will be facing when the pandemic ult imately ends WELL-POSITIONED FOR CONTINUED GROWTH New growth opportunities from acquisitions Pandemic capabilities will remain relevant Significantly expanded our MDx customer base Expanded manufacturing capabilities to support future growth + NSPH FLOW + 400 CUSTOMERS 2015: 900 CUSTOMERS 2020:

2021 GROWTH DRIVERS VERIGENE® II LAUNCH Fully automated Random access Scalable Flexible pricing XMAP® INTELLIFLEX LAUNCH Increased sensitivity and dynamic range Customer convenience features Workflow automation enhancements Software UI improvements ADDITIONAL COVID-19 OFFERINGS NxTAG® RPP + SARS- CoV-2 ARIES® Flu A/ B/ RSV + SARS-CoV-2 VERIGENE® II RSP Flex w/ SARS-CoV2 FURTHER DOUBLING OF ARIES® MANUFACTURING CAPACITY 2021 capacity of 4M+ tests per year 15

BEYOND 2021 GROWTH DRIVERS EFFECTIVE USE OF EXPANDING CASH POSITION M&A Increased dividend Share buyback Targeted R&D investment FURTHER MARKET PENETRATION ADDITIONAL ASSAY OFFERINGS All multiplex respiratory assays to include CoV-2 BSI: GP, GN & yeast CNS ARIES® menu expansion FURTHER INCREASE OF ARIES® MANUFACTURING CAPACITY 2022 capacity of 6M+ tests per year 16 $480M 2021G

complexity simplif ied. 17 LUMINEX IS AN EXCITING INVESTMENT OPPORTUNITY: THE TIME IS NOW! SERVING MULTI-BILLION DOLLAR MARKETS ($12B+) RAZOR/ RAZORBLADE MODEL (75% ANNUITY) STRONG PROFITABILITY + CASH FLOW; CASH POSITION OF ~$310M; INCREASING DIVIDEND DIVERSIFIED PRODUCT OFFERINGS EXCITING NEW PRODUCT PIPELINE 2021 ANNUAL REVENUE GUIDANCE: $480M (~15% YOY)

THANK YOU

XML

COVER PAGE Document	Jan. 12, 2021	Jan. 11, 2021
COVER PAGE [Abstract]
Written Communications	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, $0.001 par value
City Area Code	(512)
Entity Address, Address Line One	12212 Technology Blvd.,
Entity Incorporation, State or Country Code	DE
Entity File Number	000-30109
Document Type	8-K
Document Period End Date	Jan. 12, 2021
Entity Central Index Key		0001033905
Amendment Flag		false
Entity Registrant Name	LUMINEX CORPORATION
Entity Tax Identification Number	74-2747608
Entity Address, City or Town	Austin,
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78727
Local Phone Number	219-8020
Trading Symbol	LMNX
Security Exchange Name	NASDAQ
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false